HUTCHMED (China) Limited (AIM:HCM)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.61B -20.2% |
| Revenue (ttm) | 413.87M -8.8% |
| Net Income | 13.48M -96.2% |
| EPS | 0.02 -96.2% |
| Shares Out | 869.07M |
| PE Ratio | 121.57 |
| Forward PE | 52.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,894 |
| Open | 190.50 |
| Previous Close | 185.00 |
| Day's Range | 185.00 - 192.00 |
| 52-Week Range | 151.50 - 266.00 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 328.35 (+71.02%) |
| Earnings Date | Jul 30, 2026 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet... [Read more]
Financial Performance
In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for HCM stock is "Buy." The 12-month stock price target is 328p, which is an increase of 71.02% from the latest price.
News
Hutchmed announces results from Saffron Phase III trial of Orpathys, Tagrisso
Hutchmed (HCM) announces that positive high-level results from the Saffron Phase III trial showed Orpathys plus Tagrisso demonstrated a statistically significant and clinically meaningful improvement ...
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
HUTCHMED H1 Earnings Call Highlights
HUTCHMED NASDAQ: HCM reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported re...
HUTCHMED (China) Earnings Call Transcript: H1 2026
Strong first-half growth driven by China and ex-U.S. oncology sales, with robust pipeline progress including ATTC assets and Sovleplenib. Guidance maintained, profitability achieved, and significant cash reserves support continued R&D and commercial expansion.
HUTCHMED (China) Quarterly report: H1 2026
HUTCHMED (China) has published its H1 2026 quarterly earnings report on July 30, 2026.
HUTCHMED (China) Slides: H1 2026
HUTCHMED (China) has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
Hutchmed price target lowered to $14 from $16 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Hutchmed (HCM) to $14 from $16 and keeps a Neutral rating on the shares. Biotech has outperformed the broader market year to…
A Look at HUTCHMED (China) Ltd (HCM) After 4.4% Gain -- GF Value $13.93 vs Price $11.29
A Look at HUTCHMED (China) Ltd (HCM) After 4.4% Gain -- GF Value $13.93 vs Price $11.29
HUTCHMED (China) Ltd (HCM) Shares Fall 6.8% -- What GF Score of 79 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Fall 6.8% -- What GF Score of 79 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors
HUTCHMED (China) Ltd (HCM) Shares Surge 3.0% -- What GF Score of 79 Tells Investors
Hutchmed price target lowered to $17 from $20 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $17 from $20 and keeps a Buy rating on the shares. The print will likely refocus attention…
Hutchmed announces China NMPA approval for Orpathys NDA
Hutchmed (HCM) announced that the new drug application, or NDA, for Orpathys has been granted conditional approval by the China National Medical Products Administration, or NMPA, for the treatment of…
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients ...
HUTCHMED to Announce 2026 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months e...
Syndio Acquires Embrace.ai
SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business w...
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, sym...
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce...
isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce,...
Paychex Recognized as a Top WorkTech Company by TIME
Paychex named a leading HCM provider to TIME's America's Top WorkTech Companies 2026 List List identifies the most impactful and financially strong companies that have established themselves as leader...
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib's potential to address critical unmet needs in a treatment ...
Hutchmed upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Hutchmed (HCM) to Equal Weight from Underweight with a price target of $13.60, down from $13.75. The valuation of China biotech stocks has “reset to a better…
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of com...
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
Hutchmed (HCM) and Innovent Biologics jointly announce that the New Drug Application for the combination of Elunate and Tyvyt has been granted approval by the China National Medical Products Administr...
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
Innovent Biologics and Hutchmed (HCM) jointly announce that the new drug application for the combination of Tyvyt and Elunate has been granted approval by the China National Medical Products Administr...
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 mon...